203 related articles for article (PubMed ID: 36189297)
21. Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L; Dunne J; Savio M; Kalaszi M; McElheron M; Lynagh Y; O'Driscoll K; Roche C; Qureshi A; Crowley B; Conlon N; Kearney H
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200217. PubMed ID: 38547427
[TBL] [Abstract][Full Text] [Related]
22. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.
Corrales I; Giménez E; Navarro D
Clin Vaccine Immunol; 2014 May; 21(5):684-8. PubMed ID: 24623623
[TBL] [Abstract][Full Text] [Related]
24. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Munger KL; Levin LI; O'Reilly EJ; Falk KI; Ascherio A
Mult Scler; 2011 Oct; 17(10):1185-93. PubMed ID: 21685232
[TBL] [Abstract][Full Text] [Related]
25. Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
Huang J; Tengvall K; Bomfim Lima I; Hedström AK; Butt J; Brenner N; Gyllenberg A; Stridh P; Khademi M; Ernberg I; Al Nimer F; Manouchehrinia A; Hillert J; Alfredsson L; Andersen O; Sundström P; Waterboer T; Olsson T; Kockum I
Brain; 2024 Apr; ():. PubMed ID: 38630618
[TBL] [Abstract][Full Text] [Related]
26. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis.
Almohmeed YH; Avenell A; Aucott L; Vickers MA
PLoS One; 2013; 8(4):e61110. PubMed ID: 23585874
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
Gieß RM; Pfuhl C; Behrens JR; Rasche L; Freitag E; Khalighy N; Otto C; Wuerfel J; Brandt AU; Hofmann J; Eberspächer B; Bellmann-Strobl J; Paul F; Ruprecht K
PLoS One; 2017; 12(4):e0175279. PubMed ID: 28388676
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Abbott Architect, Siemens Immulite, bioMerieux Vidas, and Euroimmune assays for determination of Epstein-Barr virus serological diagnosis.
Appak O; Ozkaratas MH; Sayiner AA
J Med Virol; 2021 Nov; 93(11):6309-6316. PubMed ID: 34375007
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
30. Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.
Lie IA; Rød BE; Kvistad SS; Holmøy T; Myhr KM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Feb; 70():104530. PubMed ID: 36701908
[TBL] [Abstract][Full Text] [Related]
31. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
[TBL] [Abstract][Full Text] [Related]
32. Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
Ziaei A; Solomon O; Casper TC; Waltz M; Weinstock-Guttman B; Aaen G; Wheeler Y; Graves J; Benson L; Gorman M; Rensel M; Mar S; Lotze T; Greenberg B; Chitnis T; Waldman AT; Krupp L; James JA; Hart J; Barcellos LF; Waubant E
Mult Scler; 2024 Mar; 30(3):308-315. PubMed ID: 38332747
[TBL] [Abstract][Full Text] [Related]
33. Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
Zhou Y; Zhu G; Charlesworth JC; Simpson S; Rubicz R; Göring HH; Patsopoulos NA; Laverty C; Wu F; Henders A; Ellis JJ; van der Mei I; Montgomery GW; Blangero J; Curran JE; Johnson MP; Martin NG; Nyholt DR; Taylor BV;
Mult Scler; 2016 Nov; 22(13):1655-1664. PubMed ID: 26819262
[TBL] [Abstract][Full Text] [Related]
34. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination.
Lucas RM; Ponsonby AL; Dear K; Valery P; Pender MP; Burrows JM; Burrows SR; Chapman C; Coulthard A; Dwyer DE; Dwyer T; Kilpatrick T; Lay ML; McMichael AJ; Taylor BV; van der Mei IA; Williams D
Neurology; 2011 Jul; 77(4):371-9. PubMed ID: 21753179
[TBL] [Abstract][Full Text] [Related]
35. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
36. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
37. A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1).
Rubicz R; Yolken R; Drigalenko E; Carless MA; Dyer TD; Bauman L; Melton PE; Kent JW; Harley JB; Curran JE; Johnson MP; Cole SA; Almasy L; Moses EK; Dhurandhar NV; Kraig E; Blangero J; Leach CT; Göring HH
PLoS Genet; 2013; 9(1):e1003147. PubMed ID: 23326239
[TBL] [Abstract][Full Text] [Related]
38. Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Strautins K; Tschochner M; James I; Choo L; Dunn DS; Pedrini M; Kermode A; Carroll W; Nolan D
Mult Scler; 2014 Mar; 20(3):286-94. PubMed ID: 23886832
[TBL] [Abstract][Full Text] [Related]
39. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
40. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis.
Zivadinov R; Weinstock-Guttman B; Zorzon M; Uxa L; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M
J Neuroimmunol; 2009 Apr; 209(1-2):123-30. PubMed ID: 19232441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
